The double-edged sword: Neurotoxicity of chemotherapy

Blood Reviews

Volumn 29, Issue 2, 2015, Pages 93-100

  Magge, Rajiv S ^a   DeAngelis, Lisa M ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Chemotherapy; Delirium; Encephalopathy; Neuropathy; Seizure; Toxicity

Indexed keywords

AZACITIDINE; BLEOMYCIN; BLINATUMOMAB; BORTEZOMIB; BRENTUXIMAB VEDOTIN; CARBOPLATIN; CARFILZOMIB; CARMUSTINE; CHIMERIC ANTIGEN RECEPTOR; CHLORAMBUCIL; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; FLUDARABINE; LENALIDOMIDE; METHOTREXATE; NAVELBINE; NELARABINE; NITROSOUREA; OXALIPLATIN; POMALIDOMIDE; PROCARBAZINE; RITUXIMAB; THALIDOMIDE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE; ANGIOGENESIS INHIBITOR; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; CAC10-VCMMAE; PLATINUM COMPLEX; VINCA ALKALOID;

ACUTE BRAIN DISEASE; AGEUSIA; AMNESIA; ANOSMIA; APHASIA; ASEPTIC MENINGITIS; ATAXIA; AUTONOMIC NEUROPATHY; BACKACHE; BRACHIAL PLEXUS NEUROPATHY; BRAIN DISEASE; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; BULBAR PARALYSIS; CANCER CHEMOTHERAPY; CAUSE OF DEATH; CELL TRANSPLANTATION; CEREBELLUM DISEASE; CEREBRAL BLINDNESS; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; COMA; CONFUSION; CRANIAL NEUROPATHY; DELIRIUM; DEMENTIA; DIZZINESS; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; DYSARTHRIA; ELECTROLYTE DISTURBANCE; ENCEPHALITIS; ENGRAFTMENT SYNDROME; EXTRAPYRAMIDAL SYMPTOM; EYE DISEASE; FATIGUE; FEVER; HEADACHE; HEARING IMPAIRMENT; HEART INFARCTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC CELL; HEMIPARESIS; HERNIA; HIGH FREQUENCY HEARING LOSS; HODGKIN DISEASE; HORNER SYNDROME; HUMAN; KIDNEY DYSFUNCTION; LARGE CELL LYMPHOMA; LETHARGY; LEUKEMIA; LEUKOENCEPHALOPATHY; LHERMITTE SYMPTOM; LOCKED IN SYNDROME; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MOTOR NEUROPATHY; MULTIPLE MYELOMA; MUSCLE CRAMP; MYALGIA; MYELOMA; NAUSEA; NECK MALFORMATION; NEUROLOGIC DISEASE; NEUROMUSCULAR JUNCTION DISORDER; NEUROPATHY; NEUROTOXICITY; NONHODGKIN LYMPHOMA; NYSTAGMUS; OTOTOXICITY; PARALYSIS; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEDATION; SEIZURE; SENSORIMOTOR NEUROPATHY; SENSORY NEUROPATHY; SOLID TUMOR; SOMNOLENCE; SPINAL CORD DISEASE; TINNITUS; TRANSIENT GLOBAL AMNESIA; TREMOR; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; VESTIBULAR DISORDER; VISUAL IMPAIRMENT; VOMITING; WEAKNESS; ADVERSE EFFECTS; ANIMAL; BRAIN DISEASES; CHEMICALLY INDUCED; COMPLICATION; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOTHERAPY; NEUROTOXICITY SYNDROMES; SEIZURES;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, BISPECIFIC; ANTINEOPLASTIC AGENTS; BRAIN DISEASES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCONJUGATES; IMMUNOTHERAPY; NEUROTOXICITY SYNDROMES; ORGANOPLATINUM COMPOUNDS; RITUXIMAB; SEIZURES; VINCA ALKALOIDS;

EID: 84933180558     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2014.09.012     Document Type: Article

References (109)

1. Comeau T.B., Epstein J.B., Migas C. Taste and smell dysfunction in patients receiving chemotherapy: a review of current knowledge. Support Care Cancer 2001, 9:575-580.
2. Epstein J.B., Phillips N., Parry J., Epstein M.S., Nevill T., Stevenson-Moore P. Quality of life, taste, olfactory and oral function following high-dose chemotherapy and allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2002, 30:785-792.
3. Dietrich J., Han R., Yang Y., Mayer-Proschel M., Noble M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 2006, 5:22.
4. Dietrich J., Wen P.Y. Neurologic Complications of Chemotherapy. Cancer Neurology In Clinical Practice 2008, 287-326. Humana Press, New Jersey. D. Schiff, S. Kesari, P.Y. Wen (Eds.).
5. Graus F., Arino H., Dalmau J. Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas. Blood 2014, 123:3230-3238.
6. Younes A., Bartlett N.L., Leonard J.P., Kennedy D.A., Lynch C.M., Sievers E.L., et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010, 363:1812-1821.
7. Pro B., Perini G.F. Brentuximab vedotin in Hodgkin's lymphoma. Expert Opin Biol Ther 2012, 12:1415-1421.
8. Fanale M.A., Forero-Torres A., Rosenblatt J.D., Advani R.H., Franklin A.R., Kennedy D.A., et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res 2012, 18:248-255.
9. Gopal A.K., Bartlett N.L., Forero-Torres A., Younes A., Chen R., Friedberg J.W., et al. Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. Leuk Lymphoma 2014, [Epub in advance].
10. Younes A., Gopal A.K., Smith S.E., Ansell S.M., Rosenblatt J.D., Savage K.J., et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012, 30:2183-2189.
11. Wagner-Johnston N.D., Bartlett N.L., Cashen A., Berger J.R. Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. Leuk Lymphoma 2012, 53:2283-2286.
12. Topp M.S., Gokbuget N., Zugmaier G., Degenhard E., Goebeler M.E., Klinger M., et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012, 120:5185-5187.
13. Topp M.S., Kufer P., Gokbuget N., Goebeler M., Klinger M., Neumann S., et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011, 29:2493-2498.
14. Bargou R., Leo E., Zugmaier G., Klinger M., Goebeler M., Knop S., et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008, 321:974-977.
15. Portell C.A., Wenzell C.M., Advani A.S. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clin Pharmacol 2013, 5:5-11.
16. Topp M.S., Goekbuget N., Zugmaier G., Viardot A., Stelljes M., Neumann S., et al. Anti-CD19 BiTE blinatumomab induces high complete remission rate and prolongs overall survival in adult patients with relapsed/refractory B-Precursor Acute Lymphoblastic Leukemia (ALL). ASH Annual Meeting Abstracts 2012, 120:670.
17. Maloney D.G., Grillo-Lopez A.J., White C.A., Bodkin D., Schilder R.J., Neidhart J.A., et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997, 90:2188-2195.
18. Carson K.R., Evens A.M., Richey E.A., Habermann T.M., Focosi D., Seymour J.F., et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009, 113:4834-4840.
19. Carson K.R., Focosi D., Major E.O., Petrini M., Richey E.A., West D.P., et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009, 10:816-824.
20. Jena B., Dotti G., Cooper L.J. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 2010, 116:1035-1044.
21. Kochenderfer J.N., Rosenberg S.A. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol 2013, 10:267-276.
22. Kochenderfer J.N., Dudley M.E., Feldman S.A., Wilson W.H., Spaner D.E., Maric I., et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012, 119:2709-2720.
23. Deangelis L.M., Posner J.B. Neurologic complications of cancer 2009, Oxford University Press, New York.
24. O'Callaghan M.J., Ekert H. Vincristine toxicity unrelated to dose. Arch Dis Child 1976, 51:289-292.
25. Robertson G.L., Bhoopalam N., Zelkowitz L.J. Vincristine neurotoxicity and abnormal secretion of antidiuretic hormone. Arch Intern Med 1973, 132:717-720.
26. Dallera F., Gamoletti R., Costa P. Unilateral seizures following vincristine intravenous injection. Tumori 1984, 70:243-244.
27. Hurwitz R.L., Mahoney D.H., Armstrong D.L., Browder T.M. Reversible encephalopathy and seizures as a result of conventional vincristine administration. Med Pediatr Oncol 1988, 16:216-219.
28. Scheithauer W., Ludwig H., Maida E. Acute encephalopathy associated with continuous vincristine sulfate combination therapy: case report. Invest New Drugs 1985, 3:315-318.
29. Whittaker J.A., Parry D.H., Bunch C., Weatherall D.J. Coma associated with vincristine therapy. Br Med J 1973, 4:335-337.
30. Boranic M., Raci F. A Parkinson-like syndrome as side effect of chemotherapy with vincristine and adriamycin in a child with acute leukaemia. Biomedicine 1979, 31:124-125.
31. Byrd R.L., Rohrbaugh T.M., Raney R.B., Norris D.G. Transient cortical blindness secondary to vincristine therapy in childhood malignancies. Cancer 1981, 47:37-40.
32. Carpentieri U., Lockhart L.H. Ataxia and athetosis as side effects of chemotherapy with vincristine in non-Hodgkin's lymphoma. Cancer Treat Rep 1978, 62:561-562.
33. King K.L., Boder G.B. Correlation of the clinical neurotoxicity of the vinca alkaloids vincristine, vinblastine, and vindesine with their effects on cultured rat midbrain cells. Cancer Chemother Pharmacol 1979, 2:239-242.
34. Focan C., Olivier R., Le Hung S., Bays R., Claessens J.J., Debruyne H. Neurological toxicity of vindesine used in combination chemotherapy of 51 human solid tumors. Cancer Chemother Pharmacol 1981, 6:175-181.
35. Conter V., Rabbone M.L., Jankovic M., Fraschini D., Corbetta A., Pacheco C., et al. Overdose of vinblastine in a child with Langerhans' cell histiocytosis: toxicity and salvage therapy. Pediatr Hematol Oncol 1991, 8:165-169.
36. Pace A., Bove L., Nistico C., Ranuzzi M., Innocenti P., Pietrangeli A., et al. Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients. J Neurol Neurosurg Psychiatry 1996, 61:409-411.
37. Rosenfeld M.R., Pruitt A. Neurologic complications of bone marrow, stem cell, and organ transplantation in patients with cancer. Semin Oncol 2006, 33:352-361.
38. Saiz A., Graus F. Neurological complications of hematopoietic cell transplantation. Semin Neurol 2004, 24:427-434.
39. Faraci M., Lanino E., Dini G., Fondelli M.P., Morreale G., Dallorso S., et al. Severe neurologic complications after hematopoietic stem cell transplantation in children. Neurology 2002, 59:1895-1904.
40. Sostak P., Padovan C.S., Yousry T.A., Ledderose G., Kolb H.J., Straube A. Prospective evaluation of neurological complications after allogeneic bone marrow transplantation. Neurology 2003, 60:842-848.
41. Mathew R.M., Rosenfeld M.R. Neurologic Complications of Bone Marrow and Stem-cell Transplantation in Patients with Cancer. Curr Treat Options Neurol 2007, 9:308-314.
42. Higman M.A., Port J.D., Beauchamp N.J., Chen A.R. Reversible leukoencephalopathy associated with re-infusion of DMSO preserved stem cells. Bone Marrow Transplant 2000, 26:797-800.
43. Bauwens D., Hantson P., Laterre P.F., Michaux L., Latinne D., De Tourtchaninoff M., et al. Recurrent seizure and sustained encephalopathy associated with dimethylsulfoxide-preserved stem cell infusion. Leuk Lymphoma 2005, 46:1671-1674.
44. Fann J.R., Roth-Roemer S., Burington B.E., Katon W.J., Syrjala K.L. Delirium in patients undergoing hematopoietic stem cell transplantation. Cancer 2002, 95:1971-1981.
45. Fann J.R., Alfano C.M., Roth-Roemer S., Katon W.J., Syrjala K.L. Impact of delirium on cognition, distress, and health-related quality of life after hematopoietic stem-cell transplantation. J Clin Oncol 2007, 25:1223-1231.
46. Fann J.R., Hubbard R.A., Alfano C.M., Roth-Roemer S., Katon W.J., Syrjala K.L. Pre- and post-transplantation risk factors for delirium onset and severity in patients undergoing hematopoietic stem-cell transplantation. J Clin Oncol 2011, 29:895-901.
47. Spitzer T.R. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant 2001, 27:893-898.
48. Parker P., Chao N.J., Ben-Ezra J., Slatkin N., Openshaw H., Niland J.C., et al. Polymyositis as a manifestation of chronic graft-versus-host disease. Medicine (Baltimore) 1996, 75:279-285.
49. Tse S., Saunders E.F., Silverman E., Vajsar J., Becker L., Meaney B. Myasthenia gravis and polymyositis as manifestations of chronic graft-versus-host-disease. Bone Marrow Transplant 1999, 23:397-399.
50. Castellano-Sanchez A.A., Li S., Qian J., Lagoo A., Weir E., Brat D.J. Primary central nervous system posttransplant lymphoproliferative disorders. Am J Clin Pathol 2004, 121:246-253.
51. Richardson P.G., Briemberg H., Jagannath S., Wen P.Y., Barlogie B., Berenson J., et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006, 24:3113-3120.
52. Siegel D.S., Martin T., Wang M., Vij R., Jakubowiak A.J., Lonial S., et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012, 120:2817-2825.
53. Isoardo G., Bergui M., Durelli L., Barbero P., Boccadoro M., Bertola A., et al. Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features. Acta Neurol Scand 2004, 109:188-193.
54. Tosi P., Zamagni E., Cellini C., Plasmati R., Cangini D., Tacchetti P., et al. Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol 2005, 74:212-216.
55. Sohlbach K., Heinze S., Shiratori K., Sure U., Pagenstecher A., Neubauer A. Encephalopathy in a patient after long-term treatment with thalidomide. J Clin Oncol 2006, 24:4942-4944.
56. Richardson P.G., Mark T.M., Lacy M.Q. Pomalidomide: new immunomodulatory agent with potent antiproliferative effects. Crit Rev Oncol Hematol 2013, 88(Suppl. 1):S36-S44.
57. Richardson P.G., Siegel D., Baz R., Kelley S.L., Munshi N.C., Laubach J., et al. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood 2013, 121:1961-1967.
58. Sharma R.A., Steward W.P., Daines C.A., Knight R.D., O'Byrne K.J., Dalgleish A.G. Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies. Eur J Cancer 2006, 42:2318-2325.
59. Voorhees P.M., Laubach J., Anderson K.C., Richardson P.G. Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy. Blood 2013, 121:858.
60. Roelofs R.I., Hrushesky W., Rogin J., Rosenberg L. Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 1984, 34:934-938.
61. Thompson S.W., Davis L.E., Kornfeld M., Hilgers R.D., Standefer J.C. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 1984, 54:1269-1275.
62. van der Hoop R.G., van der Burg M.E., ten Bokkel Huinink W.W., van Houwelingen C., Neijt J.P. Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. Cancer 1990, 66:1697-1702.
63. Albers J.W., Chaudhry V., Cavaletti G., Donehower R.C. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 2011, CD005228.
64. Wolf S., Barton D., Kottschade L., Grothey A., Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 2008, 44:1507-1515.
65. Walther P.J., Rossitch E., Bullard D.E. The development of Lhermitte's sign during cisplatin chemotherapy. Possible drug-induced toxicity causing spinal cord demyelination. Cancer 1987, 60:2170-2172.
66. Ventafridda V., Caraceni A., Martini C., Sbanotto A., De Conno F. On the significance of Lhermitte's sign in oncology. J Neurooncol 1991, 10:133-137.
67. Rybak L.P. Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr Opin Otolaryngol Head Neck Surg 2007, 15:364-369.
68. Kalkanis J.G., Whitworth C., Rybak L.P. Vitamin E reduces cisplatin ototoxicity. Laryngoscope 2004, 114:538-542.
69. Dickey D.T., Wu Y.J., Muldoon L.L., Neuwelt E.A. Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. J Pharmacol Exp Ther 2005, 314:1052-1058.
70. van As J.W., van den Berg H., van Dalen E.C. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. Cochrane Database Syst Rev 2012, 5. CD009219.
71. Marshak T., Steiner M., Kaminer M., Levy L., Shupak A. Prevention of cisplatin-induced hearing loss by intratympanic dexamethasone: A Randomized Controlled Study. Otolaryngol Head Neck Surg 2014, 150:983-990.
72. Berman I.J., Mann M.P. Seizures and transient cortical blindness associated with cis-platinum (II) diamminedichloride (PDD) therapy in a thirty-year-old man. Cancer 1980, 45:764-766.
73. Lyass O., Lossos A., Hubert A., Gips M., Peretz T. Cisplatin-induced non-convulsive encephalopathy. Anticancer Drugs 1998, 9:100-104.
74. Dietrich J., Marienhagen J., Schalke B., Bogdahn U., Schlachetzki F. Vascular neurotoxicity following chemotherapy with cisplatin, ifosfamide, and etoposide. Ann Pharmacother 2004, 38:242-246.
75. Icli F., Karaoguz H., Dincol D., Demirkazik A., Gunel N., Karaoguz R., et al. Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer 1993, 72:587-593.
76. Samuels B.L., Vogelzang N.J., Kennedy B.J. Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy. Cancer Chemother Pharmacol 1987, 19:253-256.
77. Pasetto L.M., D'Andrea M.R., Rossi E., Monfardini S. Oxaliplatin-related neurotoxicity: how and why?. Crit Rev Oncol Hematol 2006, 59:159-168.
78. Loprinzi C.L., Qin R., Dakhil S.R., Fehrenbacher L., Flynn K.A., Atherton P., et al. Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium and Magnesium to Prevent Oxaliplatin-Induced Sensory Neurotoxicity (N08CB/Alliance). J Clin Oncol 2014, 32:997-1005.
79. Taieb S., Trillet-Lenoir V., Rambaud L., Descos L., Freyer G. Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients. Cancer 2002, 94:2434-2440.
80. Heinzlef O., Lotz J.P., Roullet E. Severe neuropathy after high dose carboplatin in three patients receiving multidrug chemotherapy. J Neurol Neurosurg Psychiatry 1998, 64:667-669.
81. Wernick R., Smith D.L. Central nervous system toxicity associated with weekly low-dose methotrexate treatment. Arthritis Rheum 1989, 32:770-775.
82. Aplin C.G., Russell-Jones R. Acute dysarthria induced by low dose methotrexate therapy in a patient with erythrodermic cutaneous T-cell lymphoma: an unusual manifestation of neurotoxicity. Clin Exp Dermatol 1999, 24:23-24.
83. Renard D., Westhovens R., Vandenbussche E., Vandenberghe R. Reversible posterior leucoencephalopathy during oral treatment with methotrexate. J Neurol 2004, 251:226-228.
84. Martino R.L., Benson A.B., Merritt J.A., Brown J.J., Lesser J.R. Transient neurologic dysfunction following moderate-dose methotrexate for undifferentiated lymphoma. Cancer 1984, 54:2003-2005.
85. Walker R.W., Allen J.C., Rosen G., Caparros B. Transient cerebral dysfunction secondary to high-dose methotrexate. J Clin Oncol 1986, 4:1845-1850.
86. Haykin M.E., Gorman M., van Hoff J., Fulbright R.K., Baehring J.M. Diffusion-weighted MRI correlates of subacute methotrexate-related neurotoxicity. J Neurooncol 2006, 76:153-157.
87. Shvidel L., Shtalrid M., Bairey O., Rahimi-Levene N., Lugassy G., Shpilberg O., et al. Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia. Leuk Lymphoma 2003, 44:1947-1950.
88. Cheson B.D., Vena D.A., Foss F.M., Sorensen J.M. Neurotoxicity of purine analogs: a review. J Clin Oncol 1994, 12:2216-2228.
89. Chun H.G., Leyland-Jones B.R., Caryk S.M., Hoth D.F. Central nervous system toxicity of fludarabine phosphate. Cancer Treat Rep 1986, 70:1225-1228.
90. Warrell R.P., Berman E. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol 1986, 4:74-79.
91. Vidarsson B., Mosher D.F., Salamat M.S., Isaksson H.J., Onundarson P.T. Progressive multifocal leukoencephalopathy after fludarabine therapy for low-grade lymphoproliferative disease. Am J Hematol 2002, 70:51-54.
92. Saumoy M., Castells G., Escoda L., Mares R., Richart C., Ugarriza A. Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia after treatment with fludarabine. Leuk Lymphoma 2002, 43:433-436.
93. Kiewe P., Seyfert S., Korper S., Rieger K., Thiel E., Knauf W. Progressive multifocal leukoencephalopathy with detection of JC virus in a patient with chronic lymphocytic leukemia parallel to onset of fludarabine therapy. Leuk Lymphoma 2003, 44:1815-1818.
94. Quant EC C.F.D., Wen P.Y. Neurological complications of chemotherapy in lymphoma and leukemia patients. Lymphoma and Leukemia of the Nervous System 2012, Springer, New York. T. Batchelor, L.M. Deangelis (Eds.).
95. Lazarus H.M., Herzig R.H., Herzig G.P., Phillips G.L., Roessmann U., Fishman D.J. Central nervous system toxicity of high-dose systemic cytosine arabinoside. Cancer 1981, 48:2577-2582.
96. Benger A., Browman G.P., Walker I.R., Preisler H.D. Clinical evidence of a cumulative effect of high-dose cytarabine on the cerebellum in patients with acute leukemia: a leukemia intergroup report. Cancer Treat Rep 1985, 69:240-241.
97. Dworkin L.A., Goldman R.D., Zivin L.S., Fuchs P.C. Cerebellar toxicity following high-dose cytosine arabinoside. J Clin Oncol 1985, 3:613-616.
98. Herzig R.H., Hines J.D., Herzig G.P., Wolff S.N., Cassileth P.A., Lazarus H.M., et al. Cerebellar toxicity with high-dose cytosine arabinoside. J Clin Oncol 1987, 5:927-932.
99. Openshaw H., Slatkin N.E., Stein A.S., Hinton D.R., Forman S.J. Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia. Cancer 1996, 78:1899-1905.
100. Borgeat A., De Muralt B., Stalder M. Peripheral neuropathy associated with high-dose Ara-C therapy. Cancer 1986, 58:852-854.
101. Scherokman B., Filling-Katz M.R., Tell D. Brachial plexus neuropathy following high-dose cytarabine in acute monoblastic leukemia. Cancer Treat Rep 1985, 69:1005-1006.
102. Cohen M.H., Johnson J.R., Massie T., Sridhara R., McGuinn W.D., Abraham S., et al. Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma. Clin Cancer Res 2006, 12:5329-5335.
103. Roecker A.M., Stockert A., Kisor D.F. Nelarabine in the treatment of refractory T-cell malignancies. Clin Med Insights Oncol 2010, 4:133-141.
104. Chaudhary U.B., Haldas J.R. Long-term complications of chemotherapy for germ cell tumours. Drugs 2003, 63:1565-1577.
105. Shahab N., Haider S., Doll D.C. Vascular toxicity of antineoplastic agents. Semin Oncol 2006, 33:121-138.
106. Spivack S.D. Drugs 5 years later: procarbazine. Ann Intern Med 1974, 81:795-800.
107. Glantz M.J., Jaeckle K.A., Chamberlain M.C., Phuphanich S., Recht L., Swinnen L.J., et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999, 5:3394-3402.
108. Antonini G., Cox M.C., Montefusco E., Ferrari A., Conte E., Morino S., et al. Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma. J Neurooncol 2007, 81:197-199.
109. Rubenstein J.L., Fridlyand J., Abrey L., Shen A., Karch J., Wang E., et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007, 25:1350-1356.